The effect of cabergoline on clinical and laboratory findings in active rheumatoid arthritis

Iranian Red Crescent Medical Journal

Volumn 13, Issue 10, 2011, Pages 749-751

  Mobini, M ^a   Kashi, Z ^a   Mohammad Pour, A R ^a   Adibi, E ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cabergoline; Dopamine agonist; Prolactin; Rheumatoid arthritis

Indexed keywords

CABERGOLINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; PREDNISOLONE; PROLACTIN;

ADULT; ARTHRALGIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT STIFFNESS; JOINT SWELLING; LETTER; MORNING STIFFNESS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

EID: 80755172305     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11. [11567728] [http://dx.doi.org/10.1016/S0140-6736(01)06075-5]
2. Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactinproducing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982;55:1178-83. [6752167] [http://dx.doi.org/10.1210/jcem-55-6-1178]
3. De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and autoimmunity. Pituitary 2005; 8:25-30. [16411065] [http://dx.doi.org/10.1007/s11102-005-5082-5]
4. Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sakane T. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 1999;26:1890-900. [10493666]
5. Dougados M, Duchesne L, Amor B. Bromocriptine and cyclosporine a combination therapy in rheumatoid arthritis. Arthritis Rheum 1988;31: 1333-4. [3178914] [http://dx.doi.org/10.1002/art.1780311022]
6. Marguerie C, David J, So A, Walport M. A pilot study comparing bromocriptine with D-penicillamine in the treatment of rheumatoid arthritis. Br J Rheumatol 1990;29:3.
7. Mader R. Bromocriptine for refractory rheumatoid arthritis. Harefuah 1997;133:527-9, 591.[9451892]
8. Figueroa FE, Carrión F, Martínez ME, Rivero S, Mamani I. Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 1997;36:1022-3. [9376979] [http://dx.doi.org/10.1093/rheumatology/36.9.1022]
9. Erb N, Pace AV, Delamere JP, Kitas GD. Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline. Rheumatology (Oxford) 2001;40:237-9. [11257171] [http://dx.doi.org/10.1093/rheumatology/40.2.237]
10. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-9. [7915824] [http://dx.doi.org/10.1056/NEJM199410063311403]
11. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21. [15207950] [http://dx.doi.org/10.1016/S0140-6736(04)16449-0]
12. Abhari R, Mobini M, Fakhri M. The effect of atorvastatin on clinical and laboratory findings in rheumatoid arthritis. Iran Univ Med Sci J 2008; 58:7-13.
13. Eijsbouts A, van den Hoogen F, Laan RF, Hermus RM, Sweep FC, van de Putte L. Treatment of rheumatoid arthritis with the dopamine agonist quinagolide. J Rheumatol 1999;26:2284-5. [10529161]